Screener
Prime Medicine PRME Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Prime Medicine’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053883
| (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Maturities of investments | 93,953 | 14,250 |
| Purchases of investments | (26,272) | (55,227) |
| Purchases of property and equipment | (260) | (3,994) |
| Net cash provided by (used in) investing activities | 67,421 | (44,971) |
| Cash flows provided by financing activities: | ||
| Net proceeds from stock option exercises | 416 | — |
| Proceeds from ESPP offerings | 338 | 197 |
| Proceeds from research and development funding liability | — | 6,000 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Prime Medicine's investing cash flow?
- Prime Medicine (PRME) reported investing cash flow of $24.03M in Q2 2026.
- What is the long-term trend for Prime Medicine's investing cash flow?
- Over 3 years (2021 to 2024), Prime Medicine's investing cash flow has grown at a -2.4% compound annual growth rate (CAGR), from -$73.63M to $68.46M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Prime Medicine's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude